Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00892437 |
|
Recruitment Status :
Completed
First Posted : May 4, 2009
Results First Posted : October 28, 2014
Last Update Posted : February 15, 2016
|
Sponsor:
Gilead Sciences
Information provided by (Responsible Party):
Gilead Sciences
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) versus ritonavir-boosted atazanavir (ATV+RTV) plus FTC/TDF in HIV-1 infected, antiretroviral treatment-naive adults.
Participants will be randomized in a 2:1 ratio. Randomization will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) at screening. After Week 48, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments are unblinded, at which point all participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive ATV+COBI+FTC/TDF until COBI tablets become commercially available, or until Gilead Sciences elects to terminate the study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV-1 Infection | Drug: COBI Drug: RTV Drug: ATV Drug: FTC/TDF Drug: COBI placebo Drug: RTV placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 85 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults |
| Study Start Date : | May 2009 |
| Actual Primary Completion Date : | December 2009 |
| Actual Study Completion Date : | January 2015 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
HIV/AIDS
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ATV+COBI+FTC/TDF
COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
|
Drug: COBI
Cobicistat (COBI) 150 mg tablet administered orally once daily
Other Names:
Drug: ATV Atazanavir (ATV) 300 mg capsule administered orally once daily
Other Name: Reyataz® Drug: FTC/TDF Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Other Name: Truvada® Drug: RTV placebo Placebo to match RTV administered orally once daily |
|
Active Comparator: ATV+RTV+FTC/TDF
RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
|
Drug: RTV
Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
Other Name: Norvir® Drug: ATV Atazanavir (ATV) 300 mg capsule administered orally once daily
Other Name: Reyataz® Drug: FTC/TDF Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Other Name: Truvada® Drug: COBI placebo Placebo to match COBI administered orally once daily |
Primary Outcome Measures :
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 [ Time Frame: Week 24 ]The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the missing = failure method, where participants with missing data were considered to have failed to achieve the endpoint.
Secondary Outcome Measures :
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 [ Time Frame: Week 48 ]The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the missing = failure method.
- Change From Baseline in HIV-1 RNA at Week 24 [ Time Frame: Baseline to Week 24 ]The change from baseline in log_10 HIV-1 RNA at Week 24 was analyzed.
- Change From Baseline in HIV-1 RNA at Week 48 [ Time Frame: Baseline to Week 48 ]The change from baseline in log_10 HIV-1 RNA at Week 48 was analyzed.
- Change From Baseline in CD4 Cell Count at Week 24 [ Time Frame: Baseline to Week 24 ]The change from baseline in CD4 cell count at Week 24 was analyzed.
- Change From Baseline in CD4 Cell Count at Week 48 [ Time Frame: Baseline to Week 48 ]The change from baseline in CD4 cell count at Week 48 was analyzed.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ability to understand and sign a written informed consent form
- Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
- No prior use of any approved or experimental anti-HIV drug
- Normal ECG (or if abnormal, determined by the investigator to be not clinically significant)
- Adequate renal function (estimated glomerular filtration rate ≥ 80 mL/min according to the Cockcroft-Gault formula)
- Hepatic transaminases ≤ 2.5 × upper limit of normal
- Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
- Adequate hematologic function (absolute neutrophil count ≥ 1000/mm^3; platelets ≥ 50,000/mm^3; hemoglobin ≥ 8.5 g/dL)
- Cluster of differentiation 4 (CD4) cell count > 50 cells/µL
- Serum amylase ≤ 1.5 × ULN (subjects with serum amylase >1.5 × ULN remained eligible if serum lipase is ≤ 1.5 × ULN)
- Normal thyroid-stimulating hormone
- Negative serum pregnancy test (females of childbearing potential only)
- Males and females of childbearing potential must agree to utilize highly effective contraception methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drugs
- Age ≥ 18 years
- Life expectancy ≥ 1 year
Exclusion Criteria:
- New AIDS-defining condition diagnosed within the 30 days prior to screening
- Documented drug resistance to nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), or primary PI resistance mutation(s)
- Hepatitis B surface antigen positive
- Hepatitis C antibody positive
- Participants experiencing cirrhosis
- Participants experiencing ascites
- Participants experiencing encephalopathy
- Females who are breastfeeding
- Positive serum pregnancy test (female of childbearing potential)
- Vaccinated within 90 days of study dosing
- History or family history of Long QT Syndrome or have a family history of sudden cardiac death or unexplained death in an otherwise healthy individual under the age of 30 years
- Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac conduction abnormalities
- Prolonged QTcF (QT interval corrected for heart rate using Fridericia's formula) interval at screening (eg, a prolongation of the QTcF interval of greater than 450 msec for males and greater than 470 msec for females)
- PR interval greater than or equal to 200 msec or less than or equal to 120 msec on ECG at screening
- QRS greater than or equal to 120 msec on ECG at screening
- Implanted defibrillator or pacemaker
- Subjects receiving ongoing therapy with any disallowed medications
- Current alcohol or substance use judged to potentially interfere with subject study compliance
- History of or ongoing malignancy (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
- Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
- Participation in any other clinical trial without prior approval
- Medications contraindicated for use with ATV, RTV, FTC, or TDF
- Any known allergies to the excipients of ATV capsules, RTV capsules, COBI tablets or FTC/TDF tablets
- Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00892437
Locations
Show 31 study locations
Sponsors and Collaborators
Gilead Sciences
Investigators
| Study Chair: | Marshall Fordyce, MD | Gilead Sciences |
Publications of Results:
| Responsible Party: | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT00892437 |
| Other Study ID Numbers: |
GS-US-216-0105 |
| First Posted: | May 4, 2009 Key Record Dates |
| Results First Posted: | October 28, 2014 |
| Last Update Posted: | February 15, 2016 |
| Last Verified: | January 2016 |
Keywords provided by Gilead Sciences:
|
HIV HIV-1 Antiretroviral Treatment-Naive |
Additional relevant MeSH terms:
|
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Atazanavir Sulfate Cobicistat Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents |
Antiviral Agents Anti-Infective Agents Anti-HIV Agents HIV Protease Inhibitors Protease Inhibitors Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |